Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Biotech Investing
CORRECTING and REPLACING Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2025 Financial Results Biotech Investing
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease Biotech Investing
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Biotech Investing
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection Biotech Investing
BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer Biotech Investing
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® Biotech Investing
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update Biotech Investing
